Chemours vs Eastman Chemical
CC and EMN side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CC and EMN compare
Eastman Chemical is the larger company, worth 3.7 times as much as Chemours ($7.6B against $2.1B).
Eastman Chemical grew revenue faster over the last twelve months (0.27% versus 0.07% for Chemours).
Eastman Chemical keeps more of each dollar of sales as profit, with a net margin of 6.9% compared with −2.6% at Chemours.
Both pay dividends: Chemours yields 2.6% and Eastman Chemical 5.1%.
Eastman Chemical scores higher on the StockData Score (16 against 5 for Chemours), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CC | EMN |
|---|---|---|
| Size and price | ||
| Market cap | $2.1B | $7.6B |
| Share price | $13.72 | $66.51 |
| Change, 1 year | 7.6% | 8.1% |
| Change, 5 years | −56.8% | −41.2% |
| Beta (5Y) | 1.57 | 1.10 |
| Employees | 5,700 | 13K |
| StockData Score | ||
| Total score | 5 | 16 (better) |
| Valuation score | 1 | 5 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 2 | 6 (better) |
| Valuation | ||
| P/E | – | 12.2× |
| P/S | 0.4× (better) | 0.8× |
| P/B | 13.3× | 1.2× (better) |
| EV/EBITDA | 7.2× | – |
| P/FCF | 9.8× (better) | 16.2× |
| FCF yield | 10.2% (better) | 6.2% |
| Fair value | – | $93.06 |
| Margin of safety | – | 28.5% |
| Growth | ||
| Revenue growth (TTM) | 0.07% | 0.27% (better) |
| Revenue growth, 5Y average | 3.2% (better) | 0.65% |
| Net income growth (TTM) | – | −13.3% |
| EPS growth (TTM) | – | −12.3% |
| EPS growth, 5Y average | – | 3.2% |
| Profitability | ||
| Gross margin | 15.2% | 20.6% (better) |
| Net margin | −2.6% | 6.9% (better) |
| FCF margin | 3.6% | 5.2% (better) |
| Return on equity | −71.8% | 10.4% (better) |
| Financial health | ||
| Debt / equity | 24.73 | 0.83 (better) |
| Net debt / EBITDA | 4.32 | – |
| Current ratio | 1.81 (better) | 1.57 |
| Altman Z-score | 1.42 | 2.15 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Dividend yield | 2.6% | 5.1% (better) |
| Payout ratio | – | 61.1% |
| Years of dividend growth | 0 | 16 (better) |
| Dividend growth, 5Y average | −12.5% | 4.5% (better) |
| Shareholder yield | 2.6% | 5.1% (better) |
| Ownership | ||
| Held by institutions | 90.2% | 94.1% |
| Held by insiders | 0.96% | 0.83% |
| Insider net buying, 12 months | $489K (better) | −$206K |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 9.8% | 4.9% |
Go deeper
- CC stock overview
- CC income statement
- CC valuation and score
- EMN stock overview
- EMN income statement
- EMN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.